NCT03618238View on ClinicalTrials.gov

Anlotinib for Advanced and Refractory Natural Killer /T-cell Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 25, 2018

Primary Completion Date

April 30, 2021

Study Completion Date

April 30, 2021

Conditions
Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type
Interventions
DRUG

Anlotinib

12 mg daily for continus 14 days every 21 days

Trial Locations (1)

Unknown

Xinhua Hospital, Shanghai

All Listed Sponsors
lead

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

OTHER

NCT03618238 - Anlotinib for Advanced and Refractory Natural Killer /T-cell Lymphoma | Biotech Hunter | Biotech Hunter